These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17721148)

  • 1. Preventing contrast medium-induced nephropathy.
    Kohtz C; Thompson M
    Am J Nurs; 2007 Sep; 107(9):40-9; quiz 49-50. PubMed ID: 17721148
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
    Seyon RA; Jensen LA; Ferguson IA; Williams RG
    Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing contrast nephropathy: what is the best strategy? A review of the literature.
    Cox CD; Tsikouris JP
    J Clin Pharmacol; 2004 Apr; 44(4):327-37. PubMed ID: 15051739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-induced nephropathy: we need all the data to discern the truth.
    Barrett BJ
    Am J Kidney Dis; 2009 Oct; 54(4):587-9. PubMed ID: 19781450
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of contrast-induced nephropathy in patients undergoing emergent coronary procedures.
    Bouzas-Mosquera A; Vázquez-Rodríguez JM
    Am J Cardiol; 2008 Mar; 101(6):910. PubMed ID: 18328863
    [No Abstract]   [Full Text] [Related]  

  • 6. Strategies to reduce the risk of contrast-induced nephropathy.
    Stacul F; Adam A; Becker CR; Davidson C; Lameire N; McCullough PA; Tumlin J;
    Am J Cardiol; 2006 Sep; 98(6A):59K-77K. PubMed ID: 16949381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial.
    Majumdar SR; Kjellstrand CM; Tymchak WJ; Hervas-Malo M; Taylor DA; Teo KK
    Am J Kidney Dis; 2009 Oct; 54(4):602-9. PubMed ID: 19535188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study.
    Ferrario F; Barone MT; Landoni G; Genderini A; Heidemperger M; Trezzi M; Piccaluga E; Danna P; Scorza D
    Nephrol Dial Transplant; 2009 Oct; 24(10):3103-7. PubMed ID: 19549691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetylcysteine in the prevention of contrast-induced nephropathy.
    Fishbane S
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):281-7. PubMed ID: 18003766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of contrast-induced renal dysfunction by N-acetylcysteine. Truth or myth?
    Billinger M; Hess OM; Meier B
    Eur Heart J; 2004 Feb; 25(3):188-9. PubMed ID: 14972417
    [No Abstract]   [Full Text] [Related]  

  • 12. Contrast medium use.
    Davidson C; Stacul F; McCullough PA; Tumlin J; Adam A; Lameire N; Becker CR;
    Am J Cardiol; 2006 Sep; 98(6A):42K-58K. PubMed ID: 16949380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium-induced nephrotoxicity.
    Buhaescu I; Izzedine H
    Int J Clin Pract; 2008 Jul; 62(7):1113-8. PubMed ID: 18218006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New pharmacological protocols to prevent or reduce contrast media nephropathy.
    Briguori C; Airoldi F; Morici N; Colombo A
    Minerva Cardioangiol; 2005 Feb; 53(1):49-58. PubMed ID: 15788979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contrast-induced nephropathy].
    Westenfeld R; Rump LC
    Dtsch Med Wochenschr; 2013 Apr; 138(14):715-8. PubMed ID: 23533037
    [No Abstract]   [Full Text] [Related]  

  • 16. Pathophysiology of contrast-induced nephropathy.
    Tumlin J; Stacul F; Adam A; Becker CR; Davidson C; Lameire N; McCullough PA;
    Am J Cardiol; 2006 Sep; 98(6A):14K-20K. PubMed ID: 16949376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contrast agent nephropathy.
    Nicol P; Axelson C
    Eur Heart J; 2004 Aug; 25(15):1369; discussion 1369-70. PubMed ID: 15288173
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect of amber acid on the kidney function in gentamycin-induced nephropathy in white rats].
    Hozhenko AI; Vladymyrova MP; Topor OA
    Fiziol Zh (1994); 2006; 52(5):41-6. PubMed ID: 17176838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical practice. Preventing nephropathy induced by contrast medium.
    Barrett BJ; Parfrey PS
    N Engl J Med; 2006 Jan; 354(4):379-86. PubMed ID: 16436769
    [No Abstract]   [Full Text] [Related]  

  • 20. [Strange but true: acetylcysteine protects against kidney damage caused by iodized contrast media].
    Rizzato G
    Radiol Med; 2001 Apr; 101(4):287-9. PubMed ID: 11398061
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.